Staniszewska, Anna

Stat3 controls lysosomal-mediated cell death in vivo

Kreuzaler, P. A., Staniszewska, A. D., Li, W., Omidvar, N., Kedjouar, B., Turkson, J., Poli, V., Flavell, R. A., Clarkson, R. W. E., & Watson, C. J. (2011) · Nature Cell Biology

Cell death mechanisms and regulationAutophagy in Disease and Therapy

Cited by 312

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine

Protein Kinase Regulation and GTPase SignalingRNA Interference and Gene Delivery

Cited by 177

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Floc'h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Ménard, L., Cuomo, M. E., O'Neill, D. J., Ward, R. A., Finlay, M. R. V., et al. (2018) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 115

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Sacco, A., Federico, C., Todoerti, K., Ziccheddu, B., Palermo, V., Giacomini, A., Ravelli, C., Maccarinelli, F., Bianchi, G., Belotti, A., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsAcute Myeloid Leukemia Research

Cited by 20

Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions

Riess, J., Floch, N., Martin, M., Orme, J., Staniszewska, A., Menard, L., Cuomo, M. E., O'Neill, D., Ward, R., Finlay, R., et al. (2017) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 8